LXEO
Lexeo Therapeutics, Inc.
Key Financials
Revenue
$654000
N/A
Operating Income
$-109257000
↓ 3.3%
Net Income
$-99961000
↓ 1.7%
Total Assets
$268.7M
↑ 82.9%
EPS (Diluted)
$-1.86
↑ 39.8%
Total Liabilities
$22.0M
↓ 26.8%
Shareholders' Equity
$246.7M
↑ 111.1%
Cash & Equivalents
$63.0M
↑ 79.9%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| SCHEDULE 13G | 8/14/2026 | View on SEC |
| SCHEDULE 13G/A | 8/14/2026 | View on SEC |
| SCHEDULE 13G/A | 8/14/2026 | View on SEC |
| SCHEDULE 13G/A | 8/13/2026 | View on SEC |
| 10-Q | 8/12/2026 | View on SEC |
| 8-K | 8/12/2026 | View on SEC |
| SCHEDULE 13G | 8/7/2026 | View on SEC |
| 4 | 7/1/2026 | View on SEC |
| 4 | 7/1/2026 | View on SEC |
| 4 | 7/1/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | LXEO |
| Company Name | Lexeo Therapeutics, Inc. |
| CIK | 1907108 |
| Sector | Biological Products, (No Diagnostic Substances) |
| Industry | Non-accelerated filer Smaller reporting company Emerging growth company |
| Exchange | Nasdaq |
| SIC Code | 2836 |
| SIC Description | Biological Products, (No Diagnostic Substances) |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| Phone | (212) 547-9879 |